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The peroxisome proliferator-activated receptor alpha (PPARα) is a ligand-activated transcription factor involved in the regulation
of a variety of processes, ranging from inflammation and immunity to nutrient metabolism and energy homeostasis. PPARα serves
as a molecular target for hypolipidemic fibrates drugs which bind the receptor with high affinity. Furthermore, PPARα binds and is
activated by numerous fatty acids and fatty acid-derived compounds. PPARα governs biological processes by altering the expression
of a large number of target genes. Accordingly, the specific role of PPARα is directly related to the biological function of its target
genes. Here, we present an overview of the involvement of PPARα in lipid metabolism and other pathways through a detailed
analysis of the different known or putative PPARα target genes. The emphasis is on gene regulation by PPARα in liver although
many of the results likely apply to other organs and tissues as well.
1. Introduction
Nutrient metabolism and energy homeostasis are tightly
controlled by numerous regulatory systems involving specific
transcription factors. The peroxisome proliferator-activated
receptors (PPARs) are ligand-activated transcription factors
that belong to the superfamily of nuclear hormone receptors
and play an important role in nutrient homeostasis [1–3].
Three different PPAR subtypes are known: PPARα, PPARβ/δ,
and PPARγ. All PPARs share the same molecular mode
of action via formation of heterodimers with the nuclear
receptor RXR, followed by binding to specific DNA-response
elements in target genes known as peroxisome proliferator
response elements (PPREs). PPREs are characterized by a
common core sequence consisting of a direct repeat of
the consensus sequence AGGTCA interspaced by a single
nucleotide [1, 4]. Expression of PPARα and PPARβ/δ is
found ubiquitously, whereas PPARγ is mainly expressed in
adipose tissue, macrophages, and colon [5, 6]. Activation
of transcription by PPARs is dependent on a number of
different steps including ligand binding to PPAR, binding
of PPAR to the target gene, removal of corepressors and
recruitment of coactivators, remodeling of the chromatin
structure, and finally facilitation of gene transcription [7].
This paper will focus exclusively on PPARα.
PPARα was first discovered in the early 1990s and since
then has been identified as the master regulator of hepatic
lipid metabolism [8]. In addition, PPARα has been shown
to govern glucose metabolism, lipoprotein metabolism,
liver inflammation, amino acid metabolism, and hepatocyte
proliferation (specifically in rodents). Synthetic agonists of
PPARα lower plasma triglycerides and raise plasma high-
density lipoprotein (HDL) levels and are thus used clinically
in the treatment of dyslipidemia [2, 9–11].
In recent years, the advent of microarray technology
has allowed the study of whole genome expression profiles.
Accordingly, a wealth of new information has become
available about the role of specific transcription factors in
regulation of gene expression. Combined with data collected
using more established methods, microarray has permitted
the generation of a comprehensive picture of the impact of
PPARα on gene expression, thereby providing key insight
into the functional role of PPARα. The present paper is aimed
at providing a detailed and updated overview of PPARα
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target genes in different biological processes and to highlight
possible differences between mouse and human.
Although the presence of a functional PPRE is often used
as a criteria for designating direct PPARα target genes, we did
not apply this criteria very stringently in our analysis as the
in vivo functionality of most of the identified PPREs remains
uncertain. Recent studies indicate that the standard approach
to screen for PPREs in the 1-2 kb region upstream of the
transcriptional start site (TSS) is at odds with accumulating
evidence that PPARs often bind quite distant from the TSS
[12–14]. In those cases, contact with the basal transcription
machinery is expected to be established via DNA looping.
Thus, the absence of a PPRE in the 1-2 kb region upstream
of the TSS cannot be used as a criterion to disqualify
target genes. Other aspects that need to be taken into
account include correspondence in gene function with better
established PPAR targets and the timing of gene induction
following PPARα activation.
2. PPARα Tissue Expression Profile in
Mouse and Human
High expression levels of PPARα expression are found in
liver and specifically in the parenchymal cell population.
Expression of PPARα in nonparenchymal liver cells such as
Kupffer cells is much lower [15, 16]. Other tissues with high
PPARα mRNA levels are heart, kidney, intestine, and brown
adipose tissue, all of which are characterized by an elevated
rate of fatty acid catabolism [17]. PPARα expression has
also been detected in immune cells such as the peripheral
blood mononuclear cell population, and specifically in T-
cells and macrophages [18–22]. Evidence suggests that mice
and humans share similar PPARα tissue expression profiles
[6, 17] (Figure 1). In the past, the importance of PPARα
in human liver was questioned based on data showing
approximately 10-fold lower PPARα mRNA levels in human
liver compared with mouse liver [23]. A recent study
using more advanced methodology revealed similar PPARα
expression in mouse and human liver and in mouse and
human hepatocytes, thus strongly arguing against this notion
[24]. Given that PPARα has been most extensively studied
in liver, most of the information on PPARα target genes
presented here relates to hepatic gene regulation.
3. PPARα Structure in Mouse and Human
Analogous to other nuclear receptor superfamily members,
PPARα has a domain structure consisting of an N-terminal
activating function-1 (AF-1) domain, a central DNA-binding
domain (DBD), and a C-terminal ligand-binding domain
(LBD) [25, 26]. The N-terminal domain can be phosphory-
lated leading to changes in transcriptional activity and even
ligand binding of the receptor [27]. The DBD is responsible
for physical interaction with DNA and allows PPARα to bind
to specific PPREs as a heterodimer with RXR [28]. The LBD
harbors the ligand-binding pocket crucial for dimerization
with RXR and contains the activating function-2 involved in
physical interactions with coregulatory proteins [7, 29, 30].
Comparison of human and murine PPARα shows 85%
identity at the nucleotide level and 91% identity at the amino
acid level. Data have indicated that there is some genetic
heterogeneity in the functional coding sequence of human
PPARα that translates into functional differences in receptor
activity. One identified variant of the human PPARα gene
produces a protein that is mutated within the PPARα DNA-
binding domain. This L162V gene variant exhibits greater
ligand-induced activity compared to the wild-type receptor
[31, 32]. While there is some evidence for a link between
the L162V polymorphism and metabolic parameters such as
plasma lipid levels, these correlations are not always found
[32–37]. Interestingly, the effect of L162V polymorphism has
been suggested to be modulated via gene-drug and gene-
nutrient interactions [38–40]. The V227A polymorphism
was found in Japanese population and has been associated
with altered serum lipid levels and nonalcoholic fatty liver
disease [41–44]. In addition to polymorphic variants, a
truncated splice variant of human PPARα has been described
that negatively interferes with wild-type PPARα activity [45].
4. PPARα Ligands
PPARα serves as receptor for a structurally diverse set of
compounds. The most important class of synthetic PPARα
ligands is the fibrates, including gemfibrozil, bezafibrate,
clofibrate, fenofibrate, and Wy14643 [2, 9–11, 46]. This class
of drugs is used in the treatment of dyslipidemia primarily
associated with type 2 diabetes mellitus. In addition, PPARα
is activated by plasticizers, insecticides, and other rodent
hepatic carcinogens. Natural ligands of PPARα include a
variety of fatty acids as well as numerous fatty acid derivatives
and compounds showing structural resemblance to fatty
acids, including acyl-CoAs, oxidized fatty acids, eicosanoids,
endocannabinoids, and phytanic acid [47–53]. Endogenous
ligand activation of PPARα in liver was initially suggested
to occur primarily during fasting as large amounts of free
fatty acids are released into the bloodstream and enter the
liver [54, 55]. However, compelling evidence indicates that
hepatic PPARα is not activated by plasma free fatty acids,
whereas it can be activated by dietary fatty acids and fatty
acids generated via de novo lipogenesis [56–60]. Recently, it
was shown that the effects of dietary unsaturated fatty acids
on hepatic gene expression are almost exclusively mediated
by PPARα and mimic the effect of synthetic PPARα agonists
[61].
5. PPARα and Hepatic Lipid Metabolism
Regulation of lipid metabolism is mainly coordinated by
liver, which actively metabolizes fatty acids as fuel and con-
tinuously produces very low-density lipoproteins (VLDLs)
particles to provide a constant supply of fatty acids to periph-
eral tissues. Disturbances in these pathways are the basis for
hepatic steatosis and alterations in plasma lipoprotein levels.
Many aspects of hepatic lipid metabolism are under control
of PPARα, including fatty acid uptake through membranes,
fatty acid activation, intracellular fatty acid trafficking, fatty
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Table 1: List of PPARα target genes in different biological processes in liver. Genes regulated by PPARα in mouse are shown in lower case.
Genes regulated in human and mouse are shown in CAPITAL BOLD. Genes regulated only in human are shown in CAPITAL, and genes
with detected functional PPRE are shown in italic font.
Lipid
metabolism
Lipid/hormone
transport
Adipor2 [24, 62], Cd36 [24, 62–64], LEPR [24, 62], Slc27a1 [62, 64–67], SLC27A2
[24, 62, 63, 68], SLC27A4 [24, 62]
Acyl-CoA forma-
tion/hydrolysis/
binding
Acot1 [24, 62, 69], Acot7 [62], ACOT12 [24, 62], ACSL1 [24, 62, 70–72], ACSL3 [24, 62],
Acsl4 [24, 62, 63, 73], ACSL5 [24, 62, 63], ACSM3 [24, 62], Acss2 [62], FABP1
[24, 62, 74, 75], Fabp2 [24, 62, 63], FABP3 [24, 62], Fabp4 [62, 68], Fabp5 [62]
Mitochondrial β-
oxidation/oxidative
phosphorylation
ACAA2 [24, 62, 68], Acadl [24, 62, 70, 74, 76], ACADM [24, 55, 62, 70], ACADS
[24, 54, 62, 70], ACADVL [24, 62, 63, 70], Acad8 [62], Acad9 [62], Acad10 [62], Acot2
[24, 62, 69], Acot9 [62], Acot10 [62], CPT1A [24, 54, 55, 62, 77–79], Cpt1b [24, 62],
CPT2 [24, 62, 70, 80], Crat [24, 62, 74], Dci [24, 62, 65, 68, 76], Decr1 [24, 62, 76, 81],
ETFA [24], Etfb [24, 62], ETFDH [24, 62], HADHA [24, 62, 63, 68, 82], HADHB
[24, 62, 63, 68], Hadh [24, 62, 68, 74, 76, 83], Hadh2 [62], Hibch [24, 62], SLC25A20
[24, 62, 84], SLC22A5 [24, 62, 85, 86], TXNIP [24, 62], Ucp2 [24, 62, 87–89], Ucp3 [62]
Ketogenesis/ketolysis
Acat1 [24, 62, 68], Bdh [62], FGF21 [24, 62, 90–92], Hmgcl [62], HMGCS2
[24, 62, 93–95]
Peroxisomal
β-oxidation
ABCD2 [24, 62, 96], ABCD3 [24, 62, 96], ACAA1A [24, 62, 68, 76], Acaa1b [24, 62],
Acot3 [24, 62], Acot4 [24, 62], Acot5 [24, 62], Acot8 [62, 97], ACOX1
[24, 55, 62, 68, 70, 98, 99], Crot [24, 62, 74], Decr2 [24, 62, 68, 100] ECH1
[24, 62, 63, 68], Ehhadh [24, 62, 101, 102], HACL1 [24], HSD17B4 [24, 62, 103, 104],
Peci [24, 62, 65, 100], Pex11a [24]
Microsomal
(ω-hydroxylation)
ALDH3A1 [24], Aldh3a2 [24, 62, 105], ALDH9A1 [24], Cyp4a1 [74, 106–109], Cyp4a3
[55, 74, 108], Cyp4a10 [24, 62, 68, 84, 106, 110], Cyp4a12a [24, 62, 65], Cyp4a14
[24, 62, 68, 110, 111], Cyp4f15 [24], Cyp4x1 [24]
Lipogenesis
Acaca [62], ACACB [62], AGPAT2 [62], Agpat3 [24, 62], Agpat5 [62], Agpat6 [62],
Dgat1 [62, 112], ELOVL5 [62, 113, 114], ELOVL6 [24, 62, 113, 114], Elovl7 [62], FADS1
[24, 62, 113], Fads2 [62, 113, 115], Fasn [62, 112], GPAM [24, 62, 65], Hsd17b12 [62],
Lpin2 [24, 56, 62], MLYCD [24, 62], Mogat1 [24, 62], MOD1 [24, 62, 70, 116], Scd1
[24, 62, 117, 118], Scd2 [62, 68], Slc25a10 [62, 100], Srebf1 [24, 62, 119]
Lipases/lipid droplet
proteins
ADFP [24, 62, 120], Ces1 [62], Ces3 [24, 62], Cidea [24, 62, 121], CIDEC [24, 62, 121],
Gos2 [24, 62, 122, 123], Lipa [24, 62], Lipe [24, 62, 68], Mgll [24, 62, 63, 68],
Oxpat/Lsdp5 [24, 62, 124, 125], Plin1 [24], PNPLA2 [24, 62], S3-12 [24, 62]
Lipoprotein uptake
and metabolism
ANGPTL4 [24, 62, 126, 127], APOA1 [128–133], APOA2 [24, 134], APOA5
[24, 135, 136], APOCIII [137–139], LIPC [24, 62], Lipg [62], Lpl [62, 64, 65, 140], Lrp4
[24, 62], PCTP [24, 62], Pltp [62, 65, 141, 142], Mttp [24, 62, 143], VLDLR [24, 62]
Cholesterol/Bile
transport and
metabolism
ABCA1 [24, 62, 144], ABCB4 [24, 62, 94, 144], Abcb11 [62], Abcg5 [62, 144], Abcg8
[62, 144], Cav1 [24], CYP7A1 [24, 62, 145–147], Cyp8b1 [62, 148], Cyp27a1 [145], FXR
[62], LXR [144, 149], Npc1 [62], Rab9 [24, 62], Scarb2 [62], Slc10a1 [94], Slc10a2
[62, 150]
Other pathways
Glucose/Glycerol
transport and
metabolism
AQP3 [24, 62, 151], Aqp7 [62], Aqp9 [62, 151], Fbp2 [24, 62], G6PC [24], Gpd1
[24, 62, 151], Gpd2 [62, 151], GYK [24, 62, 151], Gys-2 [152], Ldha [62], Pcx [62], PCK1
[24], Pdk1 [24], PDK4 [24, 62, 153, 154]
Biotransformation
AKR1B10 [24], AKR1C3 [24], CYP1A2 [24], Cyp2a5 [110], CYP2B6 [24], CYP2C8 [24],
CYP2C9 [24], Cyp2c11 [155], Cyp2c12 [155], Cyp2c29 [110], CYP2J2 [24], CYP3A5
[24], CYP3A7 [24], CYP3A11 [24, 110], Cyp3a43 [24], EPHX2 [24, 156], Gsta3 [157],
MGST3 [24], UGT1A9 [158]
Amino Acid
metabolism
ABAT [24, 159], Acmsd [159], AGXT2 [24, 160], Arg1 [160], ASL [24, 160], Ass1 [160],
CBS [24, 159], CPS-1 [24, 160], Cth [159], Got1 [160], Got2 [62, 64, 160, 161], Gls
[160], GLS2 [159], GPT [24, 159], Hal [159], Hpd [159], OAT [24, 159], ODC1
[24, 62, 159], OTC [24, 62, 160], PAH [24, 159], PSAT1 [24, 62, 159], Tat [159, 162]
Inflammation
Apcs [163], Birc3 [163], Cebpb [164], Cd68 [24, 165], Crp [24, 163], Cxcl10/IP10 [165],
FGB [24, 155, 166, 167], Emr1 (F4/80) [156], Icam-1 [24, 165], Ifi47 [24, 163], Igtp
[163], Nfkbia [168–170], Il-1β [165], Il-1r1 [111], Il1rn [163], Il1rap [163], Il-6
[111, 171], Il-6ra [111, 163], Il18 [163], Lcn2 [163, 165], Lifr [163], Ccl2 [165], Ccl3
[165], Mt1 [24, 163], Mt2 [163, 165], Orm2 [163], Orm3 [24, 163], Nfkb1 [24, 164],
Pla1a [24, 163], Saa2 [163], Saa4 [24, 163], Stat1 [165], Stat2 [163], Stat3 [163], Steap4
[24, 163], Stress induced protein [163], Tnfα [165], Traf2 [163], Vcam-1 [24, 165]
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Figure 1: Expression profile of PPARα in human tissues. The FirstChoice Human Total RNA Survey Panel (Ambion) was reverse transcribed
and used for qPCR using primers specific for human PPARα. Expression levels are expressed relative to small intestine, which showed the
highest expression level (100%).
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Figure 2: Schematic representation of PPARα target genes in different aspects of hepatic lipid metabolism.
acid oxidation and ketogenesis, and triglyceride storage and
lipolysis (Figure 2). It has been suggested that part of the
effect of PPARα on hepatic ketogenesis may be mediated by
induction of the PPARα target fibroblast growth factor 21
[90–92]. A detailed discussion of the specific genes within the
various lipid metabolic pathways that are targeted by PPARα
is provided below (Table 1).
5.1. Peroxisomal Fatty Acid β-Oxidation. The first link
between PPARα and fatty acid catabolism was established
by the identification of the Acyl-CoA oxidase gene, encod-
ing the rate-limiting enzyme in peroxisomal long-chain
fatty acid oxidation, as a direct PPARα target gene [98,
172]. Peroxisomes are known to be involved in many
aspects of lipid metabolism, including synthesis of bile
acids and plasmalogens, synthesis of cholesterol and iso-
prenoids, alpha-oxidation, glyoxylate and H2O2 metabolism,
and beta-oxidation of very-long-straight-chain or branched-
chain acyl-CoAs. The beta-oxidation of straight-chain acyl-
CoAs starts with a reaction catalyzed by acyl-CoA oxi-
dase 1 (Acox1) followed by one of two enzymes car-
rying both enoyl-CoA-hydratase and 3-hydroxyacyl-CoA
dehydrogenase activity (L-bifunctional enzyme, Ehhadh; D-
bifunctional enzyme, Hsd17b4) and finally peroxisomal 3-
ketoacyl-CoA thiolase (Acaa1a, Acaa1b). All genes men-
tioned above represent PPARα targets [24, 55, 62, 68, 70, 76,
98, 99, 101–104]. Additionally, genes involved in peroxisomal
fatty acid uptake (Abcd2 and Abcd3), conversion of fatty acid
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Figure 3: Vanin-1 likely represents a direct PPARα target gene. (a) Vnn1 expression in livers of ad libitum fed and 24 h fasted wildtype
and PPARα−/− mice. (b) Vnn1 expression in liver, (c) small intestine, and (d) large intestine of wildtype and PPARα−/− mice 6 h after
administration of a single oral dose of Wy14643 (4 mg), fenofibrate (4 mg), and synthetic triglycerides triolein, trilinolein, trilinolenin,
trieicosapentaenoin, or tridocosahexaenoin (400 mL). (e) HepG2 cells were transiently transfected with reporters (PPRE)3-TK-LUC or
PPRE-Vnn1-LUC (PPRE present in intron 3-4 of the Vnn1 gene cloned into pGL3-promoter) and PPARα expression plasmid (pSG5). After
transfection, cells were treated with WY14643 (50 μM) for 24 hours followed by determination of luciferase and β-galactosidase activities in
the cell lysates. Luciferase activities were normalized to β-galactosidase, and the relative luciferase activity of the cells treated with DMSO
was set to 1. Error bars represent SEM.
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to acyl-CoA (Crot), and numerous thioesterases (Acots) that
convert acyl-CoAs back to fatty acids have been reported to
be regulated by PPARα [24, 62, 74, 96, 97]. Activation of
PPARα using synthetic agonists is known to cause massive
proliferation of peroxisomes in rodents via induction of a
large set of genes encoding peroxisomal fatty acid oxidation
enzymes, as well as genes involved in peroxisomal biogenesis
(Pex genes). Chronic exposure to these so-called peroxisome
proliferators can also induce liver cancer in rodents [173].
In contrast, activation of PPARα in humans does not
seem to induce hepatocellular carcinomas, suggesting a
species specific response to PPARα activation. Initially, it
was believed that the differential response was due to the
lack activation of Acox1 and other peroxisomal genes by
PPARα in humans [71, 174, 175]. However, recent data
indicate that PPARα is able to induce a significant number
of genes involved in peroxisomal fatty acid oxidation in
human primary hepatocytes, including Acox1 [24]. Also,
PPARα-mediated induction of the Pex11a gene involved in
peroxisome proliferation is observed in both species [24].
5.2. Mitochondrial Fatty Acid β-Oxidation. The crucial role
of PPARα in mitochondrial fatty acid oxidation is illustrated
by the phenotype of fasted PPARα−/− mice, which exhibit
hypoketonemia, hepatic steatosis, and elevated plasma free
fatty acid levels [54, 55, 176]. It is now evident that virtually
every enzymatic step within the fatty acid oxidative pathway
is under control of PPARα. Specifically, PPARα induces genes
controlling fatty acid import into the mitochondria (Cpt1,
Cpt2, Slc25a20, Slc22a5), as well as the major enzymes
within the β-oxidation pathway, including various acyl-CoA
dehydrogenases (Acad, step 1), mitochondrial trifunctional
enzyme (Hadh, step 2–4), and genes involved in β-oxidation
of unsaturated fatty acid (Dci, Decr) [24, 54, 55, 62, 63, 65,
68, 70, 74, 76–86].
Additionally, synthesis of ketone bodies via mitochon-
drial HMG-CoA synthase (Hmgcs2) and HMG-CoA lyase
(Hmgcl) is governed by PPARα [24, 62, 93–95], as is the
expression of genes encoding electron transferring flavopro-
tein and the corresponding dehydrogenase (Etfa, Etfb, Etfdh)
[24, 62]. The latter proteins mediate the transfer of electrons
from Acyl-CoA dehydrogenases to the membrane-bound
electron transfer flavoprotein ubiquinone oxidoreductase,
allowing further entry into the oxidative phosphorylation
pathway [177, 178]. Finally, PPARα induces uncoupling
proteins Ucp2 and Ucp3, which have been proposed to
function as an outward transporter of nonesterified fatty acid
anions from the mitochondrial matrix [24, 62, 87–89].
5.3. Microsomal Fatty Acid ω-Hydroxylation. Cyp4A
enzymes are members of the cytochrome P450 monoxyge-
nase superfamily and catalyze microsomal ω-hydroxylation
of fatty acids [106, 179]. Studies using PPARα−/− mice have
shown that hepatic expression of Cyp4a genes is almost
completely dependent on PPARα (Cyp4a10, Cyp4a12,
Cyp4a14 in mice, Cyp4a1, Cyp4a3 in rat, Cyp4a11 in
human) [55, 62, 74, 84, 106–111]. Furthermore, expression
is extremely sensitive to PPARα ligand activation, indicating
that Cyp4a genes may serve as PPARα marker genes.
Although previous studies performed in human primary
hepatocytes could not show regulation of Cyp4a by human
PPARα, our microarray data revealed significant induction
of Cyp4a11 by Wy14643 in primary human hepatocytes
[24, 68, 180, 181]. ω-hydroxylation of saturated and
unsaturated fatty acids may lead to the generation of high-
affinity PPARα ligands, including hydroxyeicosatetraenoic
acids (HETEs), thus creating a positive feedback loop [182].
Alternatively, induction of ω-oxidation by PPARα has been
suggested to promote the degradation of the PPARα agonist
leukotriene B4 as part of a feedback mechanism aimed at
controlling the duration of the inflammatory response [53].
5.4. Hepatic Lipogenesis. Whereas PPARα is mostly known
for its ability to induce fatty acid oxidation, growing evidence
points to a role of PPARα in regulation of lipogenesis.
A functional PPRE was identified in the promoter of a
limited number of lipogenic genes including Δ6 desaturase
(Fads2), malic enzyme (Mod1), phosphatidate phosphatase
(Lpin2), and Δ9 desaturase (Scd1) [56, 115–117]. Gene
expression profiling showed that chronic in vivo treatment
of mice with PPARα agonist causes the upregulation of
a large set of lipid biosynthetic genes [62]. However,
regulation is much less pronounced in primary hepatocytes,
suggesting an indirect mechanism. Consistent with this
notion, induction of lipogenic genes by chronic PPARα
activation was completely abolished in SREBP1−/− mice
[183]. The effect of PPARα agonists on SREBP targets has
been attributed to increased activation of SREBP1c via
enhanced proteolytic cleavage [112]. Such a mechanism
may also lead to increased SREBP1 mRNA via an autoloop
regulatory circuit [184]. Alternatively, it is possible that
PPARα is recruited to promoters of SREBP targets and
stimulates SREBP activity [12]. Interestingly, in rat FAO
hepatoma cells, it was found that PPARα activation reduced
expression of lipogenic genes, including Fasn, Gpam, and
SREBP1c, while Insig1 expression was increased by PPARα
[185]. The reason for the discrepancy is not clear.
In contrast to de novo fatty acid and cholesterol synthesis,
synthesis of triglycerides may be directly targeted by PPARα.
Several genes within these pathways are upregulated by
PPARα activation, including Gpam, various Agpat genes,
Mogat1, Dgat1, and Lpin2 [24, 62, 65, 112]. Induction of
genes involved in triglyceride synthesis from fatty acids may
reflect a broader role of PPARα in the hepatic response to
fasting aimed at neutralizing large amounts of incoming
adipose tissue-derived free fatty acids.
5.5. Fatty Acid Uptake and Binding. Before they can be
metabolized in the liver, fatty acids have to be transferred
across the cell membrane. Several proteins are involved
in fatty acid transport across the plasma membrane, a
number of which carry both fatty acid transporter and acyl-
CoA synthetase activity. Studies have shown that the fatty
acid transport proteins Slc27a1, Slc27a2, and Slc27a4 are
upregulated by PPARα in liver [24, 62, 64–68, 101].
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Slc27a1 is not expressed and not regulated by PPARα in
isolated primary hepatocytes, suggesting regulation occurs in
liver macrophages (Kupffer cells). So far, the only fatty acid
transporter for which a PPAR response element has been
identified is Slc27a1. PPARα agonists also markedly induce
hepatic expression of the fatty acid transporter/scavenger
receptor Cd36, which is expressed in various liver cell types
[24, 62–64]. Additionally, expression of numerous acyl-
CoA synthetases is induced by PPARα [24, 62, 63, 70–73].
Currently, limited information is available about the cellular
localization and the structure/function relationship of acyl-
CoA synthetase enzyme [186].
The Fabp gene family comprise a group of high-affinity
intracellular fatty acid-binding proteins. Interestingly, Fabp1
was one of the first PPARα target genes identified [74,
75, 187, 188]. Recent studies indicate that Fabp1 may be
involved in partitioning of FA to specific lipid metabolic
pathways [189]. Other Fabp genes induced by PPARα
activation in mouse liver include Fabp2, Fabp3, Fabp4,
and Fabp5 [24, 62, 63]. Induction of Fabp4 (A-FABP, aP2)
upon PPARα activation likely occurs via its expression in
Kupffer cells. Fabp4 expression in hepatocytes is correlated
with acquisition of a steatotic phenotype concurrent with
upregulation of PPARγ mRNA [190].
5.6. Lipases and Lipid Droplet Proteins. PPARα−/− mice
exhibit elevated hepatic TG accumulation, especially under
fasting conditions [54, 191, 192]. Conversely, treatment with
PPARα agonists lowers hepatic triglyceride levels in models
of hepatic steatosis and can prevent the fasting-induced
increase in liver TG [193, 194]. The antisteatotic effect of
PPARα has mainly been attributed to stimulation of fatty acid
oxidation, which would decrease the availability of fatty acids
for TG storage.
Recently, hepatic lipid droplets were shown to be targeted
by autophagy, which ultimately leads to TG hydrolysis
via lysosomal acid hydrolase (Lipa). Which other lipases
importantly contribute to intracellular lipolysis of hepatic
TG stores remains unclear, but lipases active in adipocytes
likely play a role, including Ces3, Lipe, Pnpla2, Mgll, and
perhaps Pnpla3 [195–200]. With the exception of Pnpla3, all
of the above genes are induced by short-term treatment with
PPARα agonist in mouse hepatocytes. Regulation of Pnpla2
was also observed in human hepatocytes. Pnpla2 and Lipe
were previously classified as direct target genes of PPARγ in
adipose tissue, suggesting that they are direct target of PPARα
as well [201, 202]. Thus, apart from induction of fatty acid
oxidation, PPARα activation may also decrease hepatic TG
storage by stimulating the TG hydrolysis pathway.
Lipid droplets are coated with one or more mem-
bers of the perilipin family of proteins: perilipin (Plin1),
Adrp/adipophilin (Plin2), Tip47 (Plin3), S3-12 (Plin4), and
Oxpat/Lsdp5 (Plin5). Adrp and Lsdp5 have been identified
as target genes of PPARα in liver [120, 124]. A recent study
suggests that Adrp could serve as potential mediator of the
effect of PPARα on VLDL production. Adrp induction by
PPARα may diminish VLDL production by favoring fatty
acids storage in cytosolic lipid droplets rather than directing
through VLDL assembly [203]. Besides Adrp, expression of
S3-12 and perilipin, which are known as PPARγ target genes
in adipose tissue, is induced by PPARα agonist in human
hepatocytes [24, 204]. Perilipin expression in human liver is
correlated with development of steatotic liver [205].
Two recently identified lipid droplet-associated proteins
that are not part of the perilipin family are Cidec (FSp27) and
Cidea [206, 207]. Both proteins promote TG accumulation
and are targets of PPARγ in adipocytes [208, 209]. In
addition, they are regulated by PPARα in mouse liver,
although the kinetics of induction of the two genes seems to
be quite different [121]. Cidec but not Cidea upregulation
by PPARα agonist could be confirmed in human primary
hepatocytes [24].
Interestingly, the G(0)/G(1) switch gene 2 (G0s2) was
recently identified as an inhibitor of Pnpla2 activity and
located to lipid droplets in adipocytes stimulated with β-
adrenergic receptor agonist [122]. Previously, G0s2 was
shown to be a direct PPARα target gene in mouse liver and
PPARγ target in adipocytes [123]. Whether G0s2 associates
with lipid droplets in hepatocytes remains to be further
investigated. Similar to the induction of triglyceride synthe-
sis, regulation of numerous lipid droplet proteins by PPARα
reflects a broader role of PPARα in the hepatic response
to fasting aimed at deflecting large amounts of incoming
adipose tissue-derived free fatty acids towards storage in lipid
droplets.
6. PPARα and Lipoprotein Metabolism
Clinical studies in humans have provided ample evidence
that fibrate drugs effectively lower fasting plasma triglyc-
erides (TG) and raise plasma HDL [210–213]. At the
molecular level, fibrates act as synthetic agonist for PPARα,
indicating an important role of PPARα in the control of
lipoprotein metabolism. PPARα lowers plasma TG in part by
reducing very low-density lipoprotein (VLDL) production
[194]. Traditionally, this effect of PPARα was ascribed to
induction of genes involved in fatty acid oxidation and
the concomitant reduction in lipid availability for VLDL
production. However, this paper has made it evident that
in addition to its role in fatty acid catabolism, PPARα
influences multiple aspects of intracellular lipid trafficking
and metabolism, some of which may oppose hepatic TG low-
ering. Furthermore, expression of Mttp, which is involved in
the lipidation of apoB100 to form a nascent VLDL particle, is
positively regulated by PPARα [214]. Thus, the precise target
genes underlying the suppressive effect of PPARα agonist on
hepatic VLDL production remain to be fully elucidated.
In addition to suppressing VLDL production, PPARα
agonists are known to stimulate clearance of TG-rich
lipoproteins [194]. Clearance of TG-rich lipoproteins VLDL
and chylomicrons is mediated by the enzyme lipoprotein
lipase (LPL), which is attached to the capillary endothelium
of muscle and adipose tissue. Expression of Lpl in liver is
restricted to Kupffer cells and upregulated by PPARα agonists
[140, 215]. In contrast, no evidence is available indicating
a stimulatory effect of PPARα on Lpl expression in heart
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and skeletal muscle, which account for the major share
of plasma TG clearance [140, 216]. LPL activity is mostly
regulated posttranslationally via altered secretion from liver
of LPL-modulating factors, including apolipoprotein C-
III (Apoc3), apolipoprotein A-V (Apoa5), Angiopoietin-
like protein 3 (Angptl3), and Angiopoietin-like protein 4
(Angptl4). Firstly, PPARα agonists downregulate the expres-
sion of LPL inhibitor APOC3, supposedly via mechanisms
involving the transcription factors REV-ERBα, HNF4α, or
FOXO1 [137, 217–219]. Secondly, PPARα agonists increase
hepatic expression and plasma levels of APOA5, which
is a positive regulator of LPL [220]. A functional PPAR
responsive element has been identified in the promoter of
the human APOA5 gene, classifying APOA5 as a direct
PPARα target gene [135, 136]. Thirdly, PPARα upregulates
hepatic expression and plasma levels of Angptl4, which
acts as inhibitor of LPL activity by converting active LPL
dimers to inactive monomers [126]. The DNA response
element conferring PPAR regulation was located to intron
3 of the Angptl4 gene [127]. Finally, PPARα stimulates
hepatic expression of the VLDL receptor (Vldlr) [24, 62]. The
functional significance of Vldlr regulation in liver is unclear,
as Vldlr is most highly expressed in adipose tissue, heart, and
skeletal muscle, where it plays an auxiliary role in plasma TG
hydrolysis by LPL. Recently, Vldlr was shown to be under
control of PPARγ in adipocytes [221]. Thus, it appears that
both pro- and antilipolytic pathways are activated by PPARα.
Under conditions of pharmacological PPARα activation, the
prolipolytic actions of PPARα dominate, as illustrated by the
stimulation of plasma TG clearance.
PPARα agonists raise plasma HDL levels in humans,
which is most likely achieved via species specific mRNA
induction of apolipoprotein A-I (Apoa1) and A-II (Apoa2)
[128, 175, 222–224]. Apoa1 gene expression is not induced
by PPARα in rodents due to the presence of disabling
mutations within the PPAR-response element [129]. In
fact, PPARα activation in mouse downregulates Apoa1
mRNA expression and plasma concentrations through an
indirect pathway involving the PPARα-dependent induction
of the nuclear receptor REV-ERBα, a negative regulator of
transcription [129, 130, 225].
The impact of PPARα in HDL metabolism likely extends
beyond regulation of apolipoproteins. Evidence suggests
that both PPARα and PPARβ/δ stimulate expression of
endothelial lipase (Lipg) in liver [62, 226]. Endothelial lipase
mainly carries phospholipase activity and its overexpression
was shown to significantly reduce plasma HDL cholesterol
levels [227–229]. Since Lipg is expressed in endothelial cells,
macrophages, and hepatocytes, regulation of hepatic Lipg by
PPARα and PPARβ/δ may be mediated by different cell types.
In as much as PPARα agonists raise plasma HDL levels, the
physiological relevance of Lipg induction by PPARα remains
to be established.
In our recent publication, the PPARα agonist Wy14643
modestly induced hepatic lipase (Lipc) expression in primary
human hepatocytes [24]. Hepatic lipase exhibits both phos-
pholipase and triglyceride hydrolase activity and hydrolyzes
triglycerides and phospholipids of chylomicron remnants,
IDL, and HDL [230]. Whether Lipc represents a direct target
gene of PPARα in human remains unclear. Other genes
involved in lipoprotein metabolism that are regulated by
PPARα include phosphatidylcholine transfer protein (Pctp).
Induction of Pctp mRNA by PPARα is conserved in primary
human hepatocytes [24]. Pctp encodes a steroidogenic acute
regulatory-related transfer domain protein that binds with
high affinity to phosphatidylcholines. In a recent publication,
a role for Pctp in the metabolic response to PPARα was
proposed [231]. Overall, it is evident that PPARα governs
multiple aspects of plasma lipoprotein metabolism.
7. PPARα and Glucose/Glycerol Metabolism
Although PPARα has mostly been linked to fatty acid
metabolism, studies in mice have yielded considerable
evidence for a role of PPARα in hepatic glucose metabolism.
Indeed, fasted PPARα−/− mice display severe hypoglycemia
[54, 55, 176]. Several mechanisms may account for the hypo-
glycemia, including decreased hepatic glucose production
and increased peripheral glucose utilization. Genes involved
in gluconeogenesis that have been identified as PPARα
targets include phosphoenolpyruvate carboxykinase (Pck1),
pyruvate carboxylase (Pcx), and lactate dehydrogenase A
[62]. Interestingly, regulation of Pck1 by PPARα was only
observed in human hepatocytes [24]. Pyruvate carboxylase
was identified as direct target of PPARγ in adipocytes [232].
PPARα was shown to have a specific role in the metabolic
conversion of glycerol in liver by directly upregulating
expression of genes such as Gpd1, Gpd2, Gyk, Aqp3, and
Aqp9 [151]. Besides governing glucose production, PPARα
may also alter glucose utilization in numerous tissues via
induction of pyruvate dehydrogenase kinase isoform 4
(Pdk4) [153, 154, 233–236]. Pdk4 phosphorylates and inac-
tivates pyruvate dehydrogenase, thereby limiting carbon flux
through glycolysis. Synthesis of glycogen is also affected in
PPARα−/− mice, which may be mediated in part via defective
regulation of Gys2 [152]. It is noteworthy that in contrast
to studies in mice, human trials generally do not support
an effect of PPARα activation on plasma glucose levels.
Consistent with these data, it was found that upregulation of
genes involved in the glycolysis/gluconeogenesis pathway by
Wy14643 was uniquely observed in mouse hepatocytes and
not human hepatocytes [24].
8. PPARα and Hepatic
Cholesterol/Bile Metabolism
It has been demonstrated that PPARα activation increases
efflux of cholesterol to HDL. Formation of nascent HDL is
mediated by Abca1-dependent lipidation of newly-secreted
Apoa1. Expression of Abca1 is upregulated by PPARα
agonists in both human and mouse hepatocytes, as well as
in mouse intestine [24, 237]. Presently, it is not clear if this
effect of PPARα activation is mediated via LXRα, as was
shown previously in macrophages [21]. Other genes involved
in cholesterol uptake and transport that were shown to be
under control of PPARα include Abcg5, Abcg8, Cav1, Npc1,
and Rab9 [24, 62, 144].
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While PPARα is known to govern specific genes involved
in bile acid synthesis, the overall impact on bile acid
homeostasis remains somewhat ambiguous. Expression of
Cyp7a1, which represents the rate-limiting enzyme in bile
acid synthesis, is markedly downregulated in PPARα−/− mice
in fasting condition [62]. Paradoxically, synthetic PPARα
agonists reduce Cyp7a1 expression in both mice and human
[145, 238–240]. In agreement with the latter observation,
fibrate treatment leads to decreased bile acid synthesis. To
what extent the changes in Cyp7a1 expression reflect direct
regulation by PPARα is unclear as PPARα also influences
the expression of other nuclear hormone receptors involved
in regulation of Cyp7a1 such as FXR and LXR. It has also
been suggested that PPARα can antagonize LXR signaling
and LXR-dependent activation of Cyp7a1 gene promoter
[241–243].
Other genes involved in bile acid synthesis that are reg-
ulated by PPARα include Cyp27a1 which is downregulated
by PPARα agonists in a PPARα-dependent manner [145],
and Cyp8b1 which is upregulated by PPARα [62, 148].
Recently, CYP7b1 expression was shown to be suppressed
by PPARα in a sex-specific manner, which was shown
to occur via sumoylation of the LBD of PPARα [244].
Finally, PPARα stimulates expression of the hepatobiliary
phospholipid transporter Abcb4 [24, 62, 94, 144].
9. PPARα and Amino Acid Metabolism
Accumulating evidence supports a role for PPARα in regula-
tion of amino acid and urea metabolism [159, 160, 162, 245].
Studies in mice have shown that PPARα governs metabolism
of amino acids by suppressing expression of genes involved
in transamination (Aspartate amino transferase (Got1),
Alanine amino transferase (Gpt), Alanine glyoxylate amino-
transferase (Agtx2), and deamination (Glutaminase (Gls)),
as well as numerous genes that are part of the urea cycle
(Cps1, Otc, Ass1, and Asl) [160, 161, 245]. In agreement with
these data, PPARα−/− mice exhibit increased plasma urea lev-
els [160]. Several of the above genes were also downregulated
by PPARα agonist in primary human hepatocytes, suggesting
that regulation of nitrogen metabolism by PPARα is at least
partially conserved between mice and human [24].
At the present time, the mechanism behind downregu-
lation of nitrogen metabolism by PPARα remains elusive. It
has been proposed that PPARα may modulate the activity of
other transcription factors that are directly involved in amino
acid homeostasis, including HNF4α and C/EBPα [160].
However, concrete evidence supporting such a mechanism
is lacking.
Whereas PPARα activation decreases hepatic amino-
transferase expression in mice, PPARα agonists were shown
to increase expression of Gpt in human hepatocytes and
HepG2 cells, which occurred via direct regulation of the
gene promoter [161, 246]. The observed increase in plasma
alanine amino transferase activity in patients treated with
fibrates may thus be related to direct regulation of Gpt
transcription, rather than drug-induced liver injury.
10. PPARα and Inflammation
Besides regulating numerous metabolic pathways, PPARα
also governs inflammatory processes, which is mainly
achieved by downregulating gene expression via a mecha-
nism generally referred to as transrepression. The first clue
towards anti-inflammatory effects of PPARα came from
the observation that PPARα−/− mice exhibit a prolonged
inflammatory response in the ear swelling test [53]. The
anti-inflammatory effects of PPARα are likely explained by
interference of PPARα with the activity of many proinflam-
matory transcription factors including signal transducer and
activator of transcription (Stat), Activator protein-1 (AP-
1), and NF-κB [247]. Specifically, it has been shown that
activated PPARα binds to c-Jun and to the p65 subunit
of NF-κB, thereby inhibiting AP-1- and NF-κB- mediated
signaling [248]. Additionally, PPARα induces the inhibitory
protein IκBα, which normally retains NF-κB in a nonac-
tive form, leading to suppression of NF-κB DNA-binding
activity [168]. Suppression of fibrinogen gene expression
by PPARα activation is likely mediated by interference with
the transcription factor CAATT/enhancer-binding protein
(C/EBP) via sequestration of the coactivator glucocorticoid
receptor-interacting protein 1/transcriptional intermediary
factor 2 (GRIP1/TIF2) [166]. Finally, recent data indicate
that activated PPARα may downregulate gene expression by
causing the loss of STAT1 and STAT3 binding to DNA [12].
Specific genes downregulated by PPARα include a num-
ber of acute phase genes such as fibrinogen, serum amyloid
P-component, lipocalin 2, metallothioneins, and serum amy-
loid A2, which were shown to be suppressed by the PPARα
agonist Wy14643 in wild-type mice but not PPARα−/− mice
[163]. Similarly, in humans fenofibrate treatment has been
shown to decrease plasma levels of several acute phase
proteins including C-reactive protein, fibrinogen-α and -β
and interleukin 6 [166, 249, 250]. With the exception of the
sIl-1 receptor antagonist and Vanin-1, to our knowledge no
inflammatory genes have been identified as direct positive
targets of PPARα [163].
The Vanin-1 (Vnn1) gene encodes a glycosylphosphati-
dylinositol-linked membrane-associated pantetheinase that
generates cysteamine from pantothenic acid. Studies suggest
that Vanin1 may promote inflammation. Mice lacking
Vnn1 showed decreased NSAID- or Schistosoma-induced
intestinal inflammation, which was associated with higher
glutathione levels [251]. Other evidence indicates that Vanin-
1 stimulates production of inflammatory mediators by
intestinal epithelial cells and thereby controls the innate
immune response, possibly by antagonizing PPARγ activ-
ity [252]. Epithelial Vanin-1 was also found to regu-
late inflammation-driven cancer development in a colitis-
associated colon cancer model [253]. Evidence presented in
Figure 3 demonstrates that Vnn1 likely represents a direct
target gene of PPARα. Expression of Vnn1 in mouse liver
was markedly increased by fasting in wildtype but not
PPARα−/− mice (Figure 3(a)). Negligible Vnn1 expression
was detected in PPARα−/− mouse liver. Moreover, hepatic
Vnn1 expression was significantly induced by 6 h treatment
with dietary fatty acids and by the synthetic PPARα agonists
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Wy14643 and fenofibrate (Figure 3(b)). Additional data lend
strong support to the importance of PPARα in Vnn1 gene
regulation in small and large intestine (Figures 3(c) and
3(d)), although the results are not quite as striking as in
liver. Finally, it was shown that two adjacent and partially
overlapping PPREs located around 4 kb downstream of
the transcription start site of the mouse Vnn1 gene were
functional in a luciferase reporter assay in HepG2 cells
(Figure 3(e)). PPARα transfection and Wy14643 markedly
increased luciferase activity, although for reasons that remain
unclear, no synergism between the two treatments was
observed. Overall, these data suggest that Vnn1 represents a
direct PPARα target gene.
The ability of PPARα to stimulate fatty acid oxidation and
suppress hepatic inflammation has led to the exploration of
PPARα agonists as a therapeutic option for nonalcohol fatty
liver disease and specifically nonalcoholic steatohepatitis
(NASH). Several studies in mice have shown that PPARα
activation can reduce or even reverse the progression of
steatohepatitis [193, 254–259]. The inhibitory effect of
PPARα on progression of steatosis to steatohepatitis may
be mediated in part by COX2 (Ptgs2), a candidate gene
involved in steatohepatitis development that is suppressed
by PPARα [260]. In the absence of PPARα, liver steatosis
and inflammation are enhanced in mice chronically fed a
HFD [165]. Whether the effects of PPARα on NASH are
primarily related to changes in hepatic TG content or occur
via direct suppression of inflammatory genes and markers
remains unclear.
11. PPARα and Biotransformation
The detoxification of endogenous and exogenous molecules
is generally divided into three distinct biotransformation
phases. The phase I reaction involves the introduction of a
polar group into the xenobiotic molecule and is catalyzed
by members of the cytochrome P450 (CYP) superfamily
[179, 180, 261]. Phase II enzymes are responsible for covalent
linkage of the absorbed chemicals or products of the phase I
reactions with compounds such as glutathione, glucuronic
acid, or amino acids and are carried out by sulfotrans-
ferases, UDP-glucuronosyltransferases (UGTs), glutathione-
S-transferases (GSTs), and N-acetyltransferases [261]. The
third phase corresponds to elimination of the conjugated
molecule from cells and their excretion into bile or urine
via specific transporters, mainly members of the superfam-
ily ATP-binding cassette transporter proteins [262, 263].
Studies have shown that peroxisome proliferators modulate
exclusively the Cyp4a class of monooxygenases (involved in
the metabolism of biologically important compounds such
as fatty acids, see Section 5.3) in mouse while regulating
various other Cyp genes in human hepatocytes, including
members of the Cyp1a, Cyp2a, Cyp2c, and Cyp2e subfamilies
[24]. Our recent microarray data confirmed the human
specific regulation of Cyp genes belonging to classes 1-3
by PPARα in primary human hepatocytes. Interestingly, we
also observed a significant induction of another subfamily
member of Cyp4 enzymes, Cyp4x1, by PPARα in human
primary hepatocytes which was not conserved in mouse
[24]. Cyp4x1 has been shown to be involved in oxidation of
anandamide, which represents one of the endocannabinoids.
Besides upregulation of gene expression, a number of genes
involved in phase I biotransformation are downregulated by
PPARα in mice, including Cyp2a5, Cyp2c11, Cup2c12, and
Cyp2c29 [110, 155].
With respect to phase II biotransformation, PPARα has
been shown to downregulate Glutathione-S-transferase A
[GSTA], possibly leading to decreased biliary excretion of
glutathione conjugates [157, 264, 265]. In contrast, expres-
sion of UDP-glucuronosyltransferase 1A (Ugt1a9), which
participates with other UGT enzymes in glucuronidation
of bilirubin, arachidonic, and linoleic acid metabolites, is
under direct stimulatory control of PPARα [158]. Overall,
it is evident that PPARα is a major regulator of biotrans-
formation enzymes and governs the expression of numerous
cytochrome P-450 and conjugating enzymes. However, only
a small portion of the regulation seems to be conserved
between rodents and humans.
12. Conclusion
In 2010, we are celebrating the 20th anniversary of the
discovery of PPARα by Isseman and Green. PPARα was
initially isolated as a novel nuclear hormone receptor that
serves as molecular target of a diverse class of rodent hepato-
carcinogens. Since then it has become clear that PPARα can
be activated by a large variety of endogenous and synthetic
agonists including fibrate drugs. In fact, PPARα is nowadays
considered as a crucial fatty acids sensor that mediates the
effects of numerous fatty acids and fatty acid derivatives
on gene expression. Furthermore, over the years PPARα has
emerged as a crucial transcriptional regulator of numerous
metabolic and inflammatory processes. Although PPARα has
mostly been connected with stimulation of fatty acid oxida-
tion, it is now evident that the effects of PPARα are much
more widespread and cover numerous aspects of nutrient
metabolism and energy homeostasis, including metabolism
of lipoproteins, glucose/glycerol, cholesterol and bile acids,
xenobiotics, and amino acids. Certainly, PPARα merits the
classification as a master regulator of hepatic intermediary
metabolism. Until recently, much confusion surrounded the
effects of PPARα activation in human liver. Recent studies
indicate that at least in terms of lipid metabolism, the
function and specific target genes of PPARα are generally
well conserved between mouse and human. One of the major
challenges lying ahead is to gain better understanding of the
molecular mechanism underlying downregulation of gene
expression by PPARα, to improve insight into the specific
mechanisms and pathways of endogenous PPARα activation,
and to better link the functional consequences of PPARα
activation to induction of specific PPARα target genes.
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filing of promoter occupancy by PPARα in human hepatoma
cells via ChIP-chip analysis,” Nucleic Acids Research, vol. 38,
no. 9, pp. 2839–2850, 2010.
[13] M. I. Lefterova, Y. Zhang, D. J. Steger et al., “PPARγ and
C/EBP factors orchestrate adipocyte biology via adjacent
binding on a genome-wide scale,” Genes and Development,
vol. 22, no. 21, pp. 2941–2952, 2008.
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Haro, “Peroxisome proliferator-activated receptor mediates
induction of the mitochondrial 3-hydroxy-3-methylglutaryl-
CoA synthase gene by fatty acids,” Journal of Biological
Chemistry, vol. 269, no. 29, pp. 18767–18772, 1994.
[96] S. Fourcade, S. Savary, S. Albet et al., “Fibrate induction of
the adrenoleukodystrophy-related gene (ABCD2): promoter
analysis and role of the peroxisome proliferator-activated
receptor PPARα,” European Journal of Biochemistry, vol. 268,
no. 12, pp. 3490–3500, 2001.
[97] M. C. Hunt, K. Solaas, B. F. Kase, and S. E. H. Alexson,
“Characterization of an acyl-CoA thioesterase that functions
as a major regulator of peroxisomal lipid metabolism,”
Journal of Biological Chemistry, vol. 277, no. 2, pp. 1128–
1138, 2002.
[98] C. Goldberg, “The pursuit of the fictional self,” American
Journal of Psychotherapy, vol. 58, no. 2, pp. 209–219, 2004.
[99] J. C. Corton, C. Bocos, E. S. Moreno, A. Merritt, R. C. Cattley,
and J.-Å. Gustafsson, “Peroxisome proliferators alter the
expression of estrogen-metabolizing enzymes,” Biochimie,
vol. 79, no. 2-3, pp. 151–162, 1997.
[100] A. T. De Souza, X. Dai, A. G. Spencer et al., “Transcriptional
and phenotypic comparisons of Ppara knockout and siRNA
knockdown mice,” Nucleic Acids Research, vol. 34, no. 16, pp.
4486–4494, 2006.
[101] K. Alvares, C. Fan, S. S. Dadras et al., “An upstream region of
the enoyl-coenzyme A hydratase/3-hydroxyacyl- coenzyme
A dehydrogenase gene directs luciferase expression in liver
in response to peroxisome proliferators in transgenic mice,”
Cancer Research, vol. 54, no. 9, pp. 2303–2306, 1994.
[102] Y. Guo, R. A. Jolly, B. W. Halstead et al., “Underlying
mechanisms of pharmacology and toxicity of a novel PPAR
agonist revealed using rodent and canine hepatocytes,”
Toxicological Sciences, vol. 96, no. 2, pp. 294–309, 2007.
[103] J. C. Corton, C. Bocos, E. S. Moreno et al., “Rat 17β-
hydroxysteroid dehydrogenase type IV is a novel peroxisome
proliferator-inducible gene,” Molecular Pharmacology, vol.
50, no. 5, pp. 1157–1166, 1996.
[104] L.-Q. Fan, R. C. Cattley, and J. C. Corton, “Tissue-specific
induction of 17β-hydroxysteroid dehydrogenase type IV
by peroxisome proliferator chemicals is dependent on the
peroxisome proliferator-activated receptor α,” Journal of
Endocrinology, vol. 158, no. 2, pp. 237–246, 1998.
[105] T. Wang, Y. M. Shah, T. Matsubara et al., “Control of steroid
21-oic acid synthesis by peroxisome proliferator-activated
receptor α and role of the hypothalamic-pituitary-adrenal
axis,” Journal of Biological Chemistry, vol. 285, no. 10, pp.
7670–7685, 2010.
[106] E. F. Johnson, C. N. A. Palmer, K. J. Griffin, and M.-H. Hsu,
“Role of the peroxisome proliferator-activated receptor in
cytochrome P450 4A gene regulation,” FASEB Journal, vol.
10, no. 11, pp. 1241–1248, 1996.
[107] T. C. Aldridge, J. D. Tugwood, and S. Green, “Identification
and characterization of DNA elements implicated in the
regulation of CYP4A1 transcription,” Biochemical Journal,
vol. 306, no. 2, pp. 473–479, 1995.
[108] S. S.-T. Lee, T. Pineau, J. Drago et al., “Targeted disruption of
the α isoform of the peroxisome proliferator-activated recep-
tor gene in mice results in abolishment of the pleiotropic
effects of peroxisome proliferators,” Molecular and Cellular
Biology, vol. 15, no. 6, pp. 3012–3022, 1995.
[109] D. L. Kroetz, P. Yook, P. Costet, P. Bianchi, and T. Pineau,
“Peroxisome proliferator-activated receptor controls the hep-
atic CYP4A induction adaptive response to starvation and
diabetes,” Journal of Biological Chemistry, vol. 273, no. 47, pp.
31581–31589, 1998.
[110] T. B. Barclay, J. M. Peters, M. B. Sewer, L. Ferrari, F. J. Gon-
zalez, and E. T. Morgan, “Modulation of cytochrome P-450
gene expression in endotoxemic mice is tissue specific and
peroxisome proliferator-activated receptor-α dependent,”
Journal of Pharmacology and Experimental Therapeutics, vol.
290, no. 3, pp. 1250–1257, 1999.
[111] S. P. Anderson, L. Yoon, E. B. Richard, C. S. Dunn, R.
C. Cattley, and J. C. Corton, “Delayed liver regeneration
in peroxisome proliferator-activated receptor-α-null mice,”
Hepatology, vol. 36, no. 3, pp. 544–554, 2002.
[112] B. L. Knight, A. Hebbach, D. Hauton et al., “A role for PPARα
in the control of SREBP activity and lipid synthesis in the
liver,” Biochemical Journal, vol. 389, no. 2, pp. 413–421, 2005.
PPAR Research 15
[113] Y. Wang, D. Botolin, J. Xu et al., “Regulation of hepatic
fatty acid elongase and desaturase expression in diabetes and
obesity,” Journal of Lipid Research, vol. 47, no. 9, pp. 2028–
2041, 2006.
[114] Y. Wang, D. Botolin, B. Christian, J. Busik, J. Xu, and D.
B. Jump, “Tissue-specific, nutritional, and developmental
regulation of rat fatty acid elongases,” Journal of Lipid
Research, vol. 46, no. 4, pp. 706–715, 2005.
[115] C. Tang, H. P. Cho, M. T. Nakamura, and S. D. Clarke,
“Regulation of human Δ-6 desaturase gene transcription:
identification of a functional direct repeat-1 element,” Jour-
nal of Lipid Research, vol. 44, no. 4, pp. 686–695, 2003.
[116] H. Castelein, T. Gulick, P. E. Declercq, G. P. Mannaerts,
D. D. Moore, and M. I. Baes, “The peroxisome proliferator
activated receptor regulates malic enzyme gene expression,”
Journal of Biological Chemistry, vol. 269, no. 43, pp. 26754–
26758, 1994.
[117] C. W. Miller and J. M. Ntambi, “Peroxisome proliferators
induce mouse liver stearoyl-CoA desaturase 1 gene expres-
sion,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 93, no. 18, pp. 9443–9448, 1996.
[118] H. Guillou, P. Martin, S. Jan et al., “Comparative effect
of fenofibrate on hepatic desaturases in wild-type and
peroxisome proliferator-activated receptor α-deficient mice,”
Lipids, vol. 37, no. 10, pp. 981–989, 2002.
[119] G. F. Gibbons, D. Patel, D. Wiggins, and B. L. Knight,
“The functional efficiency of lipogenic and cholesterogenic
gene expression in normal mice and in mice lacking the
peroxisomal proliferator-activated receptor-alpha (PPAR-
α),” Advances in Enzyme Regulation, vol. 42, pp. 227–247,
2002.
[120] K. T. Dalen, S. M. Ulven, B. M. Arntsen, K. Solaas, and H.
I. Nebb, “PPARα activators and fasting induce the expression
of adipose differentiation-related protein in liver,” Journal of
Lipid Research, vol. 47, no. 5, pp. 931–943, 2006.
[121] N. Viswakarma, S. Yu, S. Naik et al., “Transcriptional
regulation of Cidea, mitochondrial cell death-inducing DNA
fragmentation factor α-like effector A, in mouse liver by
peroxisome proliferator-activated receptor α and γ,” Journal
of Biological Chemistry, vol. 282, no. 25, pp. 18613–18624,
2007.
[122] X. Yang, X. Lu, M. Lombès et al., “The G(0)/G(1) switch gene
2 regulates adipose lipolysis through association with adipose
triglyceride lipase,” Cell Metabolism, vol. 11, no. 3, pp. 194–
205, 2010.
[123] F. Zandbergen, S. Mandard, P. Escher et al., “The G0/G1
switch gene 2 is a novel PPAR target gene,” Biochemical
Journal, vol. 392, no. 2, pp. 313–324, 2005.
[124] T. Yamaguchi, S. Matsushita, K. Motojima, F. Hirose, and
T. Osumi, “MLDP, a novel PAT family protein localized
to lipid droplets and enriched in the heart, is regulated
by peroxisome proliferator-activated receptorα,” Journal of
Biological Chemistry, vol. 281, no. 20, pp. 14232–14240, 2006.
[125] K. T. Dalen, T. Dahl, E. Holter et al., “LSDP5 is a PAT
protein specifically expressed in fatty acid oxidizing tissues,”
Biochimica et Biophysica Acta, vol. 1771, no. 2, pp. 210–227,
2007.
[126] S. Kersten, S. Mandard, N. S. Tan et al., “Characterization of
the fasting-induced adipose factor FIAF, a novel peroxisome
proliferator-activated receptor target gene,” Journal of Biolog-
ical Chemistry, vol. 275, no. 37, pp. 28488–28493, 2000.
[127] S. Mandard, F. Zandbergen, N. S. Tan et al., “The direct
peroxisome proliferator-activated receptor target fasting-
induced adipose factor (FIAF/PGAR/ANGPTL4) is present
in blood plasma as a truncated protein that is increased by
fenofibrate treatment,” Journal of Biological Chemistry, vol.
279, no. 33, pp. 34411–34420, 2004.
[128] L. Berthou, N. Duverger, F. Emmanuel et al., “Opposite
regulation of human versus mouse apolipoprotein A-I by
fibrates in human apolipoprotein A-I transgenic mice,”
Journal of Clinical Investigation, vol. 97, no. 11, pp. 2408–
2416, 1996.
[129] N. Vu-Dac, S. Chopin-Delannoy, P. Gervois et al., “The
nuclear receptors peroxisome proliferator-activated receptor
α and rev-erbα mediate the species-specific regulation of
apolipoprotein A-I expression by fibrates,” Journal of Biologi-
cal Chemistry, vol. 273, no. 40, pp. 25713–25720, 1998.
[130] J. M. Peters, N. Hennuyer, B. Staels et al., “Alterations in
lipoprotein metabolism in peroxisome proliferator-activated
receptor α-deficient mice,” Journal of Biological Chemistry,
vol. 272, no. 43, pp. 27307–27312, 1997.
[131] N. Vu-Dac, K. Schoonjans, B. Laine, J.-C. Fruchart, J.
Auwerx, and B. Staels, “Negative regulation of the human
apolipoprotein A-I promoter by fibrates can be attenuated
by the interaction of the peroxisome proliferator-activated
receptor with its response element,” Journal of Biological
Chemistry, vol. 269, no. 49, pp. 31012–31018, 1994.
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